Home  /  Resource Library  /  Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Results of a study investigating ibrutinib combined with lenalidomide and rituximab for first line treatment of DLBCL. (Abstract only)